ProMIS Neurosciences: Insider Selling Clouds Progress on Alzheimer’s Trial
08.05.2026 - 18:41:30 | boerse-global.de
ProMIS Neurosciences finds itself in a curious bind. The biotech firm’s most advanced drug candidate, PMN310, has just hit a key recruitment milestone in its Phase 1b PRECISE-AD study, enrolling 144 patients — exceeding the original target. Yet the stock is plumbing depths not seen in a year, with shares sliding more than 11% on Friday to EUR 7.90, a new 52-week low.
The divergence between operational progress and market sentiment is stark. From its March high of EUR 21.40, the stock has lost nearly two-thirds of its value. The annualized volatility of around 95% underscores just how jittery trading has become.
A Major Shareholder Trims Its Stake
Adding to the pressure, a regulatory filing with the SEC revealed that Michael S. Gordon and Title 19 Promis have sharply reduced their position. Their stake now stands at 181,632 common shares, representing 2.0% of the roughly nine million shares outstanding as of the end of March. The filing also disclosed the conversion of 500,000 Series 2 preferred shares into common equity, alongside activity tied to earlier private placements and the exercise of warrants issued in 2024.
Investors have taken the insider reduction as a bearish signal, even though the company’s cash position looks solid. A private placement in early spring 2026 raised $175 million, enough to fund the next critical data readouts.
Should investors sell immediately? Or is it worth buying ProMIS Neurosciences?
A Different Approach to Alzheimer’s
ProMIS is betting on the oligomer hypothesis. Unlike approved Alzheimer’s therapies that target broad amyloid plaque deposits in the brain, PMN310 is designed to selectively bind only toxic amyloid-beta oligomers — the soluble aggregates widely believed to drive cognitive decline. The hope is that this precision approach can avoid the brain swelling and microbleeds that have plagued competing drugs and complicated their path to market.
Interim results from the PRECISE-AD study are expected in the first half of 2026. These will focus on whether the drug actually engages its target and moves relevant biomarkers in the right direction. A clean safety profile at this stage would be a major validation of the technology.
The full unblinded 12-month data are slated for late 2026. Those results will determine whether the selective strategy can deliver on both efficacy and safety in a real-world setting. Meanwhile, the company is also advancing preclinical programs for Parkinson’s disease and ALS.
ProMIS Neurosciences at a turning point? This analysis reveals what investors need to know now.
What’s Next
The annual shareholder meeting is scheduled for May, where management is expected to update investors on the clinical pipeline and the broader strategy for tackling complex neurodegenerative diseases. For now, the stock sits nearly 40% below its 50-day moving average — a gap that some market watchers see as a disconnect between the science and the share price.
Whether the data due later this year can close that gap is the central question hanging over ProMIS Neurosciences.
Ad
ProMIS Neurosciences Stock: New Analysis - 8 May
Fresh ProMIS Neurosciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schätzen die Börsenprofis ProMIS Aktien ein!
FĂĽr. Immer. Kostenlos.
